Equity
€195,050 ▲ 69.8%
Equity rose in 2025 from €114,838 to €195,050.
D-PHARMA
Overview
Lifetime
3 annual accounts with figures on one time axispeak €113,258 (2024)
€111,763▼ 1.3%
peak €85,743 (2024)
€80,212▼ 6.4%
peak €195,050 (2025)
€195,050▲ 69.8%
€31,413▼ 10.7%
Board1 name since 2023
1 director
Documentsfilings and deeds
29-01-202691 days before the deadline
2025micro format
Equity from €114,838 to €195,050Investments €3,132Cash from €86,321 to €128,032
Key points
from the 2025 annual accountsTurnover
≈ €340,000 estimated
The micro format states no turnover.
Investments
€3,132 4.6 × depreciation
Green is investment, beige is depreciation.
Liquidity
7.10 was 4.62 in 2024
Short-term debts fell from €32,246 to €31,413.
Starting capital
€2,500 1,000 shares
Position in the sector
€80,212
Higher net result than 94% of companies in retail trade. Sector median €4,763 · 25,208 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 39,274 companies had the same profile as D-PHARMA has now. Each dot stands for 99 companies, two years later.
95.8%
were still trading
2.3%
stopped another way
1.8%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,331 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 39,274 companies, not a prediction for D-PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director
- 999 sharesdeed of 11-08-2023
- 1 sharedeed of 11-08-2023
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0804682997
Incorporation
Founding capital of €2,500, 1,000 shares · Founders: and · Appointment: (director) · published on 11-08-2023 · Gazette deed
First establishment
Meeslaan 14, Brasschaat
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| D-PHARMA Brasschaat | €226,463 | €111,763 | 86.1% | - |
| YASMIN LIBBRECHT Antwerp | €258,250 | €93,300 | 81.2% | - |
| LIWOMA Kontich | €289,010 | €110,490 | 74.9% | - |
| Rougeardent SRL Liège | €242,680 | €125,459 | 68.3% | - |
| RS PHARMA Berchem-Sainte-Agathe | €201,141 | €121,827 | 14.0% | - |
| PHARMASOLUTIONS Linkebeek | €215,437 | €98,035 | 84.1% | - |
| NZOSSHEALTH Woluwe-Saint-Lambert | €201,994 | €89,808 | 91.5% | - |
These companies have the same main activity as D-PHARMA: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €201,000 and €289,000, founded in 2023.
Official details
Source: KBO- Status
- Active since 09-08-2023Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730and 1 other
- Establishment unit
- 2.348.067.9142930 Brasschaat, since 09-08-2023
- Financial year end
- 30 September
- Peppol
- Reachable since 05-01-2026
Annual accounts to 30-09-2025
- €111,763▼ 1.3%
- €80,212▼ 6.4%
- €195,050▲ 69.8%
- €226,463▲ 51.0%
- Filing
- Filed on 29-01-2026, 91 days before the end of the filing period
Insights on D-PHARMA
D-PHARMA files the micro format. That format states no turnover. The gross margin rose from €33,429 in 2023 to €111,763 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette.
Financials
Annual accounts 2025
micro format, filed on 29-01-2026, 91 days before the deadline€111,763
▼ 1.3%
€110,043
▼ 2.5%
€80,212
▼ 6.4%
€191,465
▲ 64.2%
86.1%
▲ 9.6 percentage points
7.10
▲ 2.48
Turnover and EBIT margin are not published. The micro format does not require them. The turnover shown is an estimate from the gross margin.
Turnover ≈ €340,000. Estimated: probably between €240,000 and €640,000.
Balance sheet
balance sheet total €226,463 on 30-09-2025What the company ownsHow it is paid for
in euro
in euro
Position in the sector
86.1%
Higher than 92% of 25,237 companies in 2025.
7.10
Higher than 91% of 24,245 companies in 2025.
35.4%
Higher than 93% of 24,434 companies in 2025.
D-PHARMA
Middle half of the sector
80% of the sector
Micro accounts in retail trade (NACE 47)
Net result: top quarter · Equity: top quarter · Balance sheet total: middle half · Working capital: top quarter
Filed annual accounts
as filed with the National Bank, click a year to choose it| Line | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Balance sheet: assets | ||||
20/58 |
226,463 | 150,012 | 42,800 | |
21/28 |
3,585 | 1,129 | - | |
22/27 |
3,585 | 1,129 | - | |
24 |
3,585 | 1,129 | - | |
29/58 |
222,878 | 148,883 | 42,800 | |
40/41 |
58,636 | 43,516 | 33,211 | |
40 |
52,831 | 43,516 | 33,211 | |
41 |
5,805 | - | - | |
54/58 |
128,032 | 86,321 | 9,585 | |
490/1 |
36,210 | 19,046 | 5 | |
| Balance sheet: equity and liabilities | ||||
10/49 |
226,463 | 150,012 | 42,800 | |
10/15 |
195,050 | 114,838 | 29,095 | |
10/11 |
2,500 | 2,500 | 2,500 | |
14 |
192,550 | 112,338 | 26,595 | |
17/49 |
31,413 | 35,174 | 13,705 | |
42/48 |
31,413 | 32,246 | 13,705 | |
44 |
2,044 | 225 | 1,086 | |
440/4 |
2,044 | 225 | 1,086 | |
45 |
29,369 | 31,782 | 9,829 | |
450/3 |
29,369 | 31,782 | 9,829 | |
47/48 |
- | 240 | 2,790 | |
492/3 |
- | 2,928 | - | |
| Income statement | ||||
9900 |
111,763 | 113,258 | 33,429 | |
630 |
676 | 106 | - | |
640/8 |
1,044 | 245 | 101 | |
9901 |
110,043 | 112,907 | 33,328 | |
65/66B |
8,684 | 3,191 | 33 | |
65 |
8,684 | 3,191 | 33 | |
9903 |
101,358 | 109,717 | 33,295 | |
67/77 |
21,146 | 23,974 | 6,700 | |
9904 |
80,212 | 85,743 | 26,595 | |
9905 |
80,212 | 85,743 | 26,595 | |
| Appropriation of the result | ||||
9906 |
192,550 | 112,338 | 26,595 | |
14P |
112,338 | 26,595 | - | |
| Document | ||||
The notes to these accounts have 5 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the filed accounts (PDF).
Source: Annual accounts 2025 (PDF), filed on 29-01-2026.
Filings
each dot is a set of accounts, on the day it reached the National BankKey figures and ratios
per financial year, computed from the annual accounts| Line | Trend | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| 110,718 | 113,013 | - | ||
| 80,888 | 85,848 | - | ||
| 3,132 | 1,234 | - | ||
| 41,711 | 76,736 | - | ||
| 191,465 | 116,637 | 29,095 | ||
| 86.1% | 76.6% | 68.0% | ||
| 7.10 | 4.62 | 3.12 | ||
| 0.16 | 0.31 | 0.47 | ||
| 41.1% | 74.7% | 91.4% | ||
| 35.4% | 57.2% | 62.1% | ||
| 12.75 | 35.42 | - |
A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.
Investments
fixed assets acquired| Item | 30-09-2025 | 30-09-2024 | 30-09-2023 |
|---|---|---|---|
| Tangible fixed assets | €3,132 | €1,234 | - |
| €676 | €106 | - |
Source: notes to the 2023 to 2025 annual accounts (statement of fixed assets)
Insights on D-PHARMA
The operating result for 2025 is 3% lower than in 2024.
Debt's share of the balance-sheet total falls from 23.4% to 13.9%. Equity is higher and debt is lower.
Board & ownership
Board
1 director, since incorporationDirector (not named in the articles)
appointed by deed of 11-08-2023
term without a fixed end
listed in the 2025 annual accounts, filed on 29-01-2026
Mandates through the years
1 name, the dashed line is todayDirector (not named in the articles)
Board
Mandates as a list
-
- Director (not named in the articles), appointed by deed of 11-08-2023, still in office
Control
Founders
,
This company
D-PHARMA
Equity €195,050
Profit €80,212 in 2025
Capital
- Contribution
- €2,500
- Shares
- 1,000
- Contribution per share
- €2.50
- Equity per share
- €195 in 2025
- Source
- deed of 11-08-2023
Articles of association
deed of 11-08-2023 (in Dutch)- Board ruleThese rules set how the board is made up, meets and takes decisions.
- At least 1 director
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Last Friday of March at 20:00
- Statutory auditorA statutory auditor is a registered auditor who checks the annual accounts. Small companies need not have one.
- No statutory auditor
Shareholders
At incorporation
deed of 11-08-2023 ↗
- 999 shares (99.9%)
- 1 share (0.1%)
Network & group
No group
D-PHARMA has no parent and no holdings in its annual accounts. is the only director. D-PHARMA shares no director with another company.
At the same address
Meeslaan 14, 2930 Brasschaat · 1 other company| Van Den Plas, Ann (sole trader)
establishment since 01-09-2017 |
founded in 2017 0682.465.571 |
Timeline
Timeline
9 events since 2023Filings
Financial
Establishments
2023202420252026
Deadline for the 2026 accounts: 30-04-2027
2026
Annual accounts 2025 filed PDFmicro format · 91 days before the deadline
Registered in the Peppol Directory Reachable for e-invoices through 0208:0804682997
2025
Equity above €150,000 equity €195,050 ▲69.8% With a profit in every financial year since 2023, equity grows to €195,050.
Annual accounts 2024 filed PDFmicro format · 2 days before the deadline
2024
Highest result from 2023 to 2025 net €85,743 ▲222% The operating result of €112,907 and the net result of €85,743 are both a record.
Equity above €100,000 equity €114,838 ▲295% With a profit in every financial year since 2023, equity grows to €114,838.
Annual accounts 2023 filed PDFmicro format · 1 day before the deadline
2023
IncorporationFounding capital of €2,500, 1,000 shares · Founders: and · Appointment: (director) · published on 11-08-20235 points ▸
- Founder,
- Founder,
- Founding capital, €2,500, 1,000 shares
- Board rule, 1
- Director appointment, (director (not named in the articles))
- The deed holds 1 more point.
First establishment Meeslaan 14, Brasschaat
Financial milestones sit on the financial year-end date, not the filing date.
Sources: Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Identity
- Enterprise number
- 0804.682.997
- VAT number
- BE 0804.682.997
- Peppol ID
- 0208:0804682997
- Other Peppol ID
- 9925:BE0804682997
- Legal form
- Private limited company
- Status
- Active, normal situation
- Founded
- 09-08-2023
- Financial year
- ends on 30 September
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Last Friday of March at 20:00deed of 11-08-2023 (in Dutch)
- Peppol
- Reachable since 05-01-2026Follow this company and you will hear the next morning if it leaves the Peppol register.
- Name
- D-PHARMA in Dutch
- Entity type
- Legal entity
- Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
- “Vlaams Gewest”“Meeslaan 14, 2930 Brasschaat”deed of 11-08-2023 (in Dutch)
Activities
NACEBEL 202547730
Retail sale of pharmaceutical products main activity
Codes under NACEBEL 2008
47730
Retail trade main activity
82990
Other business support services
- PurposeThe purpose describes the activities the company may carry out under its articles.
- “Het beleggen,het intekenen op,vast overnemen,plaatsen,kopen,verkopen en verhandelen van…”deed of 11-08-2023 (in Dutch)
12 activities
- Het beleggen,het intekenen op,vast overnemen,plaatsen,kopen,verkopen en verhandelen van aandelen,deelbewijzen,obligaties,warrants,certificaten,schuldvorderingen,gelden en andere roerende waarden,uitgegeven door Belgische of buitenlandse ondernemingen al dan niet onder de vorm van handelsvennootschappen,administratiekantoren,instellingen en verenigingen al dan niet met een (semi)-publiekrechtelijk statuut.
- Het beheren van beleggingen en van participaties in dochtervennootschappen,het waarnemen van bestuurdersfuncties,het verlenen van advies,management en andere diensten aan of in overeenstemming met de activiteiten die de vennootschap zelf voert.Deze diensten kunnen worden geleverd krachtens contractuele of statutaire benoemingen en in de hoedanigheid van externe raadgever of orgaan van de cliënt.
- Het verstrekken van leningen en voorschotten onder eender welke vorm of duur,aan alle verbonden ondernemingen of ondernemingen waarin ze een participatie bezit,alsmede het waarborgen van alle verbintenissen van zelfde ondernemingen.
- De vennootschap kan optreden als bestuurder,volmachtdrager,mandataris of vereffenaar in andere vennootschappen of ondernemingen.
- De vennootschap kan in het algemeen alle commerciële,industriële,financiële,roerende of onroerende handelingen verrichten in rechtstreeks of onrechtstreeks verband met haar voorwerp of welke van aard zouden zijn de verwezenlijking ervan geheel of ten dele te vergemakkelijken.
- De activiteiten van een apotheker evenals het voorzien van vervangingen in andere apotheken in overeenstemming met de geldende wettelijke en eventuele deontologische bepalingen;
- De uitbating van één of meerdere apotheken,de klein- en groothandel,de aan- en verkoop,de bereiding van allerlei scheikundige,farmaceutische,para-farmaceutische,drogisterijproducten,cosmetica,hygiënische en gezondheidsproducten evenals van alle aanverwante producten,waaronder parfumerie,dieetproducten,natuurvoeding…;
- De aan- en verkoop en reparaties van allerlei soorten producten die betrekking hebben op de gezondheid van de mens,waaronder hoor- en gezichtsapparatuur…;
- De handel in allerlei soorten producten evenals het verlenen van ondersteunende diensten die betrekking hebben op voormelde activiteiten.
- Het aanleggen,het oordeelkundig uitbouwen en beheren van een roerend vermogen;alle verrichtingen met betrekking tot roerende goederen en rechten,van welke aard ook,zoals de aan- en verkoop,de huur en verhuur,de ruil;in het bijzonder het beheer en de valorisatie van alle verhandelbare waardepapieren,aandelen,obligaties,staatsfondsen.
- Het aanleggen,het oordeelkundig uitbouwen en beheren van een onroerend vermogen;alle verrichtingen met betrekking tot onroerende goederen en onroerende zakelijke rechten,zoals de aan- en verkoop,de bouw,de verbouwing,de binnenhuisinrichting en decoratie,de huur en verhuur,de ruil,de verkaveling en,in het algemeen,alle verrichtingen die rechtstreeks of onrechtstreeks betrekking hebben op het beheer of op het productief maken,van onroerende goederen of onroerende zakelijke rechten.
- Het verlenen van diensten en adviezen aan derden en het verstrekken van prestaties op financieel,technisch,juridisch,logistiek,commercieel of administratief vlak.Dit zowel voor eigen rekening,voor rekening van derden of in deelneming met derden.Deze opsomming dient te worden geïnterpreteerd in de meest ruime zin.
Registered office and establishments
1 establishment| Establishment | Since | Unit number |
|---|---|---|
| Meeslaan 14 registered office 2930 Brasschaat | 09-08-2023 | 2.348.067.914 |
Buildings and parcels at the address
- Ground area
- 366 m²
- Buildings
- 88 m²
- Volume, LiDAR
- 624 m³
- Tallest building
- 9.5 m
Buildings to scale, each on its own parcel
Parcels
| Cadastral parcel | Area | Buildings | Height / floors |
|---|---|---|---|
| 11324D0306/00Z005 | 366 m² | 1 · 88 m² | 9.5 m · 3 |